Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7532307 | 0.88 | PDE2A (0.33) | KDM4EALDH1A1KMT2APDE2APDE10A | |
| SCHEMBL5202844 | 0.82 | PDE2A (0.35) | KDM4EALDH1A1KMT2APDE2APDE10A | |
| SCHEMBL7526323 | 0.81 | PDE2A (0.34) | KDM4EKMT2APDE2APDE10AHTT | |
| SCHEMBL7562074 | 0.79 | CRHR1 (0.31) | — | |
| SCHEMBL6209661 | 0.78 | PDE2A (0.37) | KDM4EALDH1A1KMT2APDE2APDE10A | |
| SCHEMBL5726642 | 0.78 | PDE2A (0.33) | KDM4EKMT2APDE2APDE10AHTT | |
| SCHEMBL7527087 | 0.76 | PDE2A (0.35) | KDM4EALDH1A1KMT2APDE2APDE10A | |
| SCHEMBL7471708 | 0.74 | NR1H2 (0.38) | SMN1; SMN2 | |
| SCHEMBL5726786 | 0.74 | PTGES (0.37) | KMT2APDE2APDE10AHTTCHRNB2 | |
| SCHEMBL6976749 | 0.74 | PDE2A (0.35) | KDM4EALDH1A1KMT2APDE2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417187-B2 | PALLADIUM CATALYZED ARYLATION, ALKYLATION, DEIODINATION OR DEBROMINATION | DOW AGROSCIENCES LLC | 2002-07-09 | — | — | US | disclosed |
| US-20020019370-A1 | Palladium catalyzed arylation, alkylation, deiodination or debromination | DOW AGROSCIENCES LLC | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019370-A1 | Palladium catalyzed arylation, alkylation, deiodination or debromination | DDT, TYR, DDC | KDM4E 510/4885ALDH1A1 792/4885PKM 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.